WORCESTER, Mass. (AP) — Generex Biotechnology Corp. said Thursday the Food and Drug Administration approved experimental use of its diabetes drug candidate Generex Oral-lyn. The FDA approved what is called a treatment investigational new drug program, which allows drug makers to make unapproved drug available to patients with dangerous illnesses who don't have a satisfactory treatment. Generex Oral-lyn will be provided to patients with life-threatening type 1 or type 2 diabetes who are not eligible for a current late-stage trial. The company makes drugs that are taken through the inner lining of the mouth, for use against metabolic diseases.